Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001643 · ClinicalTrials.gov registry record

Gene Analysis of Parkinson's Disease

A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).

Completed
Registry status
320
Enrollment target

NCT00001643: Completed study, sponsored by National Human Genome Research Institute (NHGRI).

NCT00001643 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 320 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001643 has completed, sponsored by National Human Genome Research Institute (NHGRI).

COMPLETED
Registry status
320 participants
Enrollment target

Study Summary

The purposes of this study are to identify the gene or genes responsible for an inherited form of Parkinson's disease and learn more about how the disease develops. In Parkinson's disease, a deficiency of a brain chemical called dopamine impairs the function of the part of the brain that controls movement. As a result, patients may have difficulty moving or they may have uncontrolled movements of their hands and fingers. Parkinson's disease usually occurs sporadically, with no known cause. In a few families, however, the disease seems to be inherited through a gene mutation (change). There is a 50-50 chance that a parent with the mutated gene will pass it on to a child. Children who do inherit the abnormal gene may or may not go on to actually develop Parkinson's disease-the relative chance of this happening is not known. Individuals 18 years of age and older from families in which Parkinson's disease appears to be inherited may be eligible for this study. Participants will have their medical records reviewed, provide a personal and family medical history (by telephone or in person), and have a small blood sample (2 tablespoons) taken for genetic studies. The total time required for the study is about 1 to 2 hours. Participants are encouraged to meet with a NIH investigator or with a genetics specialist in their local area before testing to talk about the possible implications for themselves and their families of the test results....

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 1997-08-29

What the finished NCT00001643 record still lists

NCT00001643 is an observational study that tracks outcomes without assigning an intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00001643 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00001643 about?

NCT00001643 is a clinical study titled "Gene Analysis of Parkinson's Disease". The purposes of this study are to identify the gene or genes responsible for an inherited form of Parkinson's disease and learn more about how the disease develops. In Parkinson's disease, a deficiency of a brain chemical called dopamine impairs the function of the part of the brain that controls m...

What is the current status of trial NCT00001643?

This trial is currently completed. The enrollment target is 320 participants. The study started on 1997-08-29.

Who is sponsoring clinical trial NCT00001643?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02763683 · 320 participants

    Investigations of Dementia in Parkinson Disease

  • NCT03331198 · 320 participants · Phase 1

    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  • NCT03458832 · 320 participants

    Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

  • NCT03551951 · 320 participants

    Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00001643, the US trial registry maintained by the National Library of Medicine. NCT00001643 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.